Generic Cometriq Availability
Last updated on Jan 8, 2025.
Cometriq is a brand name of cabozantinib, approved by the FDA in the following formulation(s):
COMETRIQ (cabozantinib s-malate - capsule;oral)
-
Manufacturer: EXELIXIS
Approval date: November 29, 2012
Strength(s): EQ 20MG BASE [RLD], EQ 80MG BASE [RLD]
Has a generic version of Cometriq been approved?
No. There is currently no therapeutically equivalent version of Cometriq available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cometriq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,091,439
Patent expiration dates:
- January 15, 2030✓
- January 15, 2030
-
Patent 11,091,440
Patent expiration dates:
- January 15, 2030✓
- January 15, 2030
-
Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Patent 11,098,015
Issued: August 24, 2021
Inventor(s): Brown Adrian St. Clair & Lamb Peter & Gallagher William P.
Assignee(s): Exelixis, Inc.Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide.
Patent expiration dates:
- January 15, 2030✓
- January 15, 2030
-
Patent 11,298,349
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Patent 12,128,039
Patent expiration dates:
- February 10, 2032✓✓
- February 10, 2032
-
Patent 7,579,473
Patent expiration dates:
- August 14, 2026✓✓
- August 14, 2026
-
(L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Patent 8,877,776
Issued: November 4, 2014
Inventor(s): Brown Adrian St. Clair & Lamb Peter & Gallagher William P.
Assignee(s): Exelixis, Inc.Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane -1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-ffuorophenyl)cyclopropane-1,1-dicarboxamide.
Patent expiration dates:
- October 8, 2030✓✓✓
- October 8, 2030
-
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
Patent 9,717,720
Issued: August 1, 2017
Inventor(s): Wilson Jo Ann & Shah Khalid
Assignee(s): Exelixis, Inc.The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
More about Cometriq (cabozantinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.